# Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

> **NCT07544953** · NA · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 60 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Lecanemab
- **OTHER:** Lecanemab non-administration group

## Key facts

- **NCT ID:** NCT07544953
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2030-06
- **Final completion:** 2030-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07544953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07544953, "Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07544953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*